Closing on Nov. 3: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc.

Sector: In Vitro And In Vivo Diagnostic Substances Region: NY, United States

: | OTC Markets: CEMID

Chembio Diagnostics, Inc. (CEMI.QB) through its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures and markets proprietary point-of-care diagnostic tests, including rapid tests for HIV. Chembio’s proprietary rapid tests participate in the growing global demand for quick, accurate and cost effective screening and confirmation of infectious diseases.

Investor Calendar

Aug 8, 2018 4:30 pm | Q2 Earnings Call

May 9, 2018 4:30 pm | Q1 Earnings Call

Mar 8, 2018 4:30 pm | Q4 Earnings Call

Nov 8, 2017 4:30 pm | Q3 Earnings Call

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?


Feb 19 2013

Chembio Diagnostics, Inc. video


Chembio Diagnostics, Inc. video


Chembio Diagnostics, Inc. video

DPP SYP SC Rev 1.mp4

Chembio Diagnostics, Inc. video



John Sperzel, President and Chief Executive Officer
John J. Sperzel joined Chembio Diagnostic Systems, Inc. in March 2014, and serves as President and Chief Executive Officer (CEO) and as a member of the Board of Directors. Prior to joining the company, Mr. Sperzel served as President and CEO at ITC, a Point of Care Diagnostics company owned by Warburg Pincus. He previously held executive leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim. Mr. Sperzel received a B.S. in Business Administration/Management from Plymouth State College and serves as an advisor to the Board of the Diagnostic Marketing Association.
Richard J. Larkin, Chief Financial Officer
Mr. Larkin oversees Chembio’s financial activities and information systems. He has been Chief Financial Officer of Chembio Diagnostic Systems, Inc. since September 2003. Prior to joining Chembio Diagnostic Systems Inc., Mr. Larkin served as CFO at Visual Technology Group from May 2000 to September 2003. He led their consultancy program providing hands-on expertise in all aspects of financial service, including initial assessment of client financial reporting requirements within an Enterprise Resource Planning (Manufacturing) environment. Prior to joining VTG, he served as CFO at Protex International Corporation from May 1987 to January 2000. Mr. Larkin holds a BBA in Accounting from Dowling College and is a member of the American Institute of Certified Public Accountants.
Javan Esfandiari, Senior Vice President of Research & Development
Senior Vice President of Research & Development In 1993 Mr. Esfandiari co-founded Sinovus Biotech AB, a Swedish biotech company where he served as Director of R&D for lateral flow technology until Chembio Diagnostic Systems, Inc. acquired Sinovus in 2000. From 1993 to 1997, Mr. Esfandiari was Director of R&D for On-Site Biotech, which was a joint venture between Sweden’s National Veterinary Institute and Sinovus. In this capacity Mr. Esfandiari was responsible for the development of rapid veterinary diagnostic tests. He has over 18 years’ experience in the diagnostic field during and over this period has developed more than 30 rapid point-of-care diagnostic products in the human and veterinary fields. He is the inventor of Chembio’s patented Dual Path Platform (DPP®) technology as well as several other diagnostic technologies patented in the US and globally. He has been the Principal or Co-Principal Investigator in research grants funded by the NIH, WHO, Gates and other national/international organizations and has co-authored over 30 publications on infectious diseases, immunology, vaccines and immunodiagnostic developments. Mr. Esfandiari received his B.Sc. in Clinical Chemistry and studied to M. Sc. Level in Molecular Biology from Lund University, Sweden.
Tom Ippolito, VP, Regulatory Affairs, QA & QC
Mr. Ippolito joined Chembio in June 2005. He has over 20 years experience with in vitro diagnostics for infectious diseases, protein therapeutics, vaccine development, Process Development, Regulatory Affairs and Quality Management. Over the years, Mr. Ippolito has held Vice President level positions at Biospecific Technologies, Corp., Director level positions in Quality Assurance, Quality Control, Process Development and Regulatory Affairs at United Biomedical, Inc. Mr. Ippolito is also the Course Director "drug development process" and "FDA regulations", a BioScience Certificate program at New York State University of Stony Brook.
Sharon Klugewicz, Chief Operating Officer
Sharon Klugewicz has been COO since May 2013 and joined Chembio in September 2012 as Vice President of Quality Assurance/Quality Control (“QA/QC”) and Technical Operations. Ms. Klugewicz is responsible for all QA/QC operations including leading Chembio’s manufacturing groups responsible for technology transfer from R&D to operations, process improvements, validations, and product investigations, to address the Company’s rapid growth in point-of-care diagnostic products and technologies. Ms. Klugewicz joins Chembio from Pall Corporation, a world leader in filtration, separation and purification technologies, where her most recent role was Sr. Vice President, Scientific & Laboratory Services (SLS). In this role, she was responsible for operational and scientific staff management globally. During her more than 20 years of experience since joining Pall as a molecular biologist, Ms. Klugewicz held a number of positions in the Pall Life Sciences Division, in Marketing, Product Management, and Field Technical Services, including Sr. Vice President, Global Quality Operations. Ms. Klugewicz holds an M.S. in Biochemistry from Adelphi University and a B.S. in Neurobiology from Stony Brook University.
Michael Steele, VP Sales, Marketing & Business Development
Mr. Steele joined Chembio in August 2012 as Vice President of Sales, Marketing & Business Development. Mr. Steele brings to Chembio a 20-year record of driving growth in general management, corporate business development, strategic account sales, alliance management, and strategy formulation and execution at life sciences companies. Since April 2012 Mr. Steele has been engaged by Chembio as Corporate Business Development Consultant. From 2008 to 2011 he was Vice President, Business Development of Seracare Life Sciences, Inc., a global provider of products and services to in-vitro diagnostic and biopharmaceutical manufacturers. In that role, he was responsible for strategic plan formulation, corporate business development and strategy projects. Prior to that he was Director and Managing Director at Serologicals Corporation (acquired by Millipore, Inc.), where he had business development, general management and operational responsibilities. Mr. Steele has also held senior business development roles at smaller biotechnology companies, including Corautus Genetics Inc. and Life Therapeutics Ltd. Mr. Steele received a Master of Business Administration and a Bachelor of Science from James Madison University.

News & Analysis